Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYXGet Rating) have been given a consensus rating of “Buy” by the eight brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $38.00.

Several research analysts have recently commented on the stock. Oppenheimer assumed coverage on shares of Ventyx Biosciences in a research note on Tuesday, February 1st. They set an “outperform” rating and a $30.00 price target on the stock. Zacks Investment Research upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 26th. Canaccord Genuity Group assumed coverage on shares of Ventyx Biosciences in a research note on Thursday, March 31st. They issued a “buy” rating on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of Ventyx Biosciences in a research note on Thursday, March 31st. They issued a “buy” rating and a $30.00 target price on the stock.

Shares of VTYX opened at $13.19 on Friday. The business’s fifty day simple moving average is $12.14. Ventyx Biosciences has a 12 month low of $9.50 and a 12 month high of $26.00.

Institutional investors have recently modified their holdings of the business. Citigroup Inc. bought a new stake in Ventyx Biosciences in the 4th quarter valued at $56,000. California State Teachers Retirement System bought a new stake in Ventyx Biosciences in the 4th quarter valued at $114,000. Wells Fargo & Company MN bought a new stake in Ventyx Biosciences in the 4th quarter valued at $121,000. Deutsche Bank AG bought a new stake in Ventyx Biosciences in the 4th quarter valued at $126,000. Finally, Parametric Portfolio Associates LLC bought a new stake in Ventyx Biosciences in the 4th quarter valued at $217,000. 60.05% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile (Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus.

Read More

Analyst Recommendations for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.